AMBS (AMBS) Stock Price & Analysis
AMBS (AMBS) rose 0.00% to USD 0 as of June 10, 2026 at 05:56 UTC, according to Nexqual real-time market data.
AMBS last closed at USD 0; the session ranged USD 0–0 on volume of 7,020 shares. Market capitalization is $63,040, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 05:56 UTC.
Key Statistics (as of June 10, 2026 at 05:56 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 7,020 shares |
| Market Cap | $63,040 |
| Exchange | PNK |
Technical Analysis (AMBS)
Nexqual's technical model rates AMBS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 05:56 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (AMBS)
Wall Street analysts rate AMBS "None", per Nexqual as of June 10, 2026 at 05:56 UTC.
| Consensus Rating | None |
|---|
Earnings (AMBS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2016-03-31 | USD -0.14 vs est -0.13 ▼ miss |
| 2015-12-31 | USD -0.8 vs est -0.59 ▼ miss |
| 2015-09-30 | USD -0.98 vs est -0.55 ▼ miss |
| 2015-06-30 | USD -1.08 vs est -1.12 ▲ beat |
Source: Nexqual, June 10, 2026 at 05:56 UTC.
Financials & Fundamentals (AMBS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.02 |
| Total Cash | $178 |
| Total Debt | $20.72M |
Source: Nexqual, June 10, 2026 at 05:56 UTC.
Financial Health Score (AMBS)
Nexqual rates AMBS's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $178 cash vs $21M debt |
| Cash Flow | Weak — Operating cash flow -$5M |
| Efficiency | Mixed — No data |
Ownership (AMBS)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 630.41M |
Source: Nexqual, June 10, 2026 at 05:56 UTC.
Leadership (AMBS)
AMBS is led by John Wesley Commissiong (age 80), Chief Scientific Officer, Director & Member of Scientific Advisory Board, per Nexqual as of June 10, 2026 at 05:56 UTC.
| Chief Scientific Officer, Director & Member of Scientific Advisory Board | John Wesley Commissiong (age 80) |
|---|---|
| Compliance Officer & Director | Robert Lewis Harris (age 81) |
| Director of Investor Relations | Aimee Boutcher |
| Senior Vice President of Business Development | Ravi Kiron (age 65) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELTP | Elite Pharmaceuticals, Inc. | USD 0.36 | ▼ 7.72% |
| TOMDF | TODOS MEDICAL LIMITED | USD 0 | ▲ 0% |
| BIEI | Premier Biomedical Inc | USD 0 | ▲ 18.18% |
| PLPL | Plandai Biotechnology, Inc. | USD 0 | ▲ 0% |
| EXMT | Anything Technologies Media Inc | USD 0 | ▼ 20% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:56 UTC. This page is informational and not investment advice.